彭布罗利珠单抗
肺癌
医学
抗体
免疫疗法
癌症研究
免疫学
癌症
肿瘤科
内科学
作者
Mao Lin,Haihua Luo,Shuyu Liang,Jibing Chen,Aihua Liu,Lizhi Niu,Yong Jiang
摘要
BACKGROUND. The anti–programmed cell death 1 (anti–PD-1) antibody pembrolizumab is clinically active against non–small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also express PD-1. This study aimed to investigate the safety and efficacy of pembrolizumab plus allogeneic NK cells in patients with previously treated advanced NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI